

## The premier conference for improving your gerontological practice

CARE . CONTINUITY . CONNECTION

# 2022 Annual Conference

September 15-17, 2022

Preconference Workshops on September 14<sup>th</sup>



Hyatt Regency Grand Cypress Orlando, FL

Orlando



The University of Alabama at Birmingham





GAPNA PRESIDENT

## atalies Bakers

Associate Professor DNP, CRNP, GS-C, CNE, FAANP, FAAN BSN 1985, MSN 1990, DNP 2010

Located in one the nation's premier academic health science centers, the UAB School of Nursing is leading the transformation of nursing's diversified workforce, making discoveries that translate into better health and quality of life, improving health through new access and care models, and impacting outcomes locally and globally.

www.uab.edu/nursing

### **Conference Welcome**





On behalf of the GAPNA Board of Directors and the National Office team, welcome to the 2022 GAPNA Annual Conference! We are pleased to continue to offer the conference in a hybrid format with onsite and virtual participation. I want to extend a special thank you to the 2022 Conference Planning Committee members, Michele Talley (chair), Patti Parker, Amy Imes, Ron Ordona, Leslie Chang Evertson, and Rosalind Caumban, and Midge Bowers as board liaison, for their time and effort in planning robust and diverse sessions.

We have now officially entered our fourth decade as an association proudly supporting gerontological advanced practice nurses, as well as all nurses and interprofessionals dedicated to the care and well-being of older adults. We strive as always to support the personal and professional growth of our members through nursing continuing professional development, member engagement, networking, and advocacy opportunities.

Conference session content will be presented by national experts and GAPNA leaders addressing the latest information, evidence, and practice approaches relevant to advanced practice nurses and others caring for older adults. This year we welcome Dr. Winifred Quinn, Director, Advocacy and Consumer Affairs, Center to Champion Nursing in America, AARP, as keynote presenter to address "Full Practice Authority Framing: The Business Case and The Health Equity Position." We also welcome Dr. Maria Shirey, Dean of The University of Alabama at Birmingham School of Nursing, to present a special highlighted session on "Resiliency Across Roles and Settings."

For our onsite attendees, we hope you will attend the inaugural GAPNA Gallery. This networking reception will allow attendees to stop by different tables and learn more about our committees and special interest groups. Our goal is for everyone to feel welcomed and be engaged in this professional organization.

We invite all attendees to connect using the GAPNA Conference Event Page (gapna.org/live), the main source of information for conference content. Here you will participate in onsite discussions, virtual chats, social wall posts, and complete the conference session evaluations! Welcome and enjoy the conference!

Notalie Baren

Natalie Baker, DNP, CRNP, GS-C, CNE, FAANP, FAAN President, GAPNA

### **Table of Contents**

| Conference Schedule                                |
|--|
| Membership Meeting/Awards Luncheon Schedule        |
| GAPNA Foundation Awards                            |
| GAPNA Podium and Poster Awards16                   |
| GAPNA Awards for Excellence                        |
| Strategtic Partners                                |
| Program-at-a-Glance                                |
| 2022 Conference Sponsors                           |
| Hotel Floor Plans24                                |
| NCPD Information and Disclosures                   |
| Conference Event Page/Online Library Information27 |
| NCPD Poster Presentations                          |
| Non-NCPD Poster Presentations                      |
| Exhibit Hall Floor Plan                            |
| Exhibitors   |
| 2023 Calls for Abstracts 35                        |

## Keep the conversation going during the 2022 GAPNA Annual Conference!

## Follow the action on social media with #GAPNA22 on Facebook @GAPNA or on Twitter and Instagram @GAPNA\_HQ

Let us know where you're traveling or checking in from virtually, how sessions are going, or what you're doing in your down time.

Give your friends and colleagues at home a look into your conference experience when logging in from Facebook or Twitter.

Find us wherever you go! Get GAPNA news and updates instantly. Join the conversation with a community of colleagues who value what you have to say.







### Wednesday, September 14, 2022

7:00 am – 7:00 pm Registration Open

8:00 am - 4:30 pm Pre-Conference Workshop

010 Gerontological Specialist Certification Exam Review Workshop – R (6.5 CH which includes 1.5 hours of pharmacology credit)

Megan Pratt, DNP, APRN, FNP-BC, GS-C; Geraldine Kanne, MSN, ANP-BC, GS-C; Myla Magno, DNP, APRN, GNP-BC, GS-C, PMHNP-BC

**Learning outcome:** After completing the Gerontological Specialist Certification Exam Review Workshop, the participant will be able to apply knowledge related to proficiencies for the APRN gerontological specialist in preparation for the APRN specialty certification in gerontology examination.

8:00 am – 11:30 am Pre-Conference Workshop
020 Suturing Workshop

(3.0 CH)

Bryan Combs, PhD, CRNP, FNP-BC, ONP-C, CNL; Tracie White, DNP, CRNP, ACNP-BC, CNOR, CRNFA

**Learning outcome:** After completing this learning activity, the participant will be able to apply the correct process for proper aseptic, anesthetic, and suturing techniques for advanced practice nurses.

12:00 pm – 5:00 pm Pre-Conference Workshop

030 Pharmacology Workshop: Part 1 − Psychiatric Medication Update & Part 2 − New Treatments for COVID-19 − R

(4.5 CH which includes 4.5 hours of pharmacology credit)

Aimee Morrison, PhD, CRNP, PMHNP-BC; Patti Parker, PhD, APRN, CNS, AGNP-BC, GS-C

**Learning outcome:** After completing this learning activity, the participant will be able to identify available and effective treatment options and apply pharmacological principles into clinical decision-making.

12:30 pm (tee time) GAPNA Foundation Golf Outing (Off-Site)

#### Session Kev

Look for these codes to find sessions and activities offering extra education support to GAPNA Conference attendees.

 $\bigcirc$  Live-streamed session | AC = Acute Care track |  $\bigcirc$  = Pharmacology hours offered |  $\bigcirc$  Ticketed event

### **Thursday, September 15, 2022**

6:30 am - 5:30 pm **Registration Open** 

7:00 am - 8:00 am Industry-Supported Presentation Theater 9

Breakfast will be provided. Attendees will be admitted on a first-come basis.

The Journey to Proper Debridement with Collagenase SANTYL◊ Ointment

Moderator: Kristina Tiskowitz, MSN, RN, CWS Amy Bruggemann, MSN, APRN-BC, CWS

The journey to proper debridement with collagenase SANTYLO ointment begins now! Join us as we explore the many challenges of chronic wound healing and how debridement with SANTYL ointment paves a path for healing chronic wounds and burns. During this discussion we will review the complex burden of chronic wounds, the TIME principles, the science behind SANTYL ointment, and clinical evidence and case studies.

Sponsored by Smith & Nephew, Inc.

8:00 am - 8:15 am Welcome/Introduction

8:15 am - 9:15 am Kevnote Address

120 Full Practice Authority Framing: The Business Case and The Health **Equity Position** (1.0 CH)

Winifred Quinn, PhD, FAANP(H), FAAN(H)

Learning outcome: After completing this learning activity, the participant will be able to focus on the patient first in their messaging and framing the full practice authority issue for two different audiences.

9:15 am - 10:45 am **Grand Opening Exhibit Hall/Coffee Break/ Raffle Basket Auction** 

10:45 am - 12:15 pm Highlighted Session 9 130 Resiliency Across Roles and Settings (1.5 CH)

Maria Shirey, PhD, MBA, RN, NEA-BC, ANEF, FACHE, FNAP, FAAN

Learning outcome: After completing this learning activity, the participant will be able to define the concept of resiliency and how to apply resiliency strategies to enhance personal and environmental well-being across practice settings.

#### Session Kev

Look for these codes to find sessions and activities offering extra education support to GAPNA Conference attendees.

🥯 Live-streamed session | 🗚 = Acute Care track | 🤻 = Pharmacology hours offered | 📟 Ticketed event

### 12:30 pm – 1:30 pm Industry-Supported Presentation Theater

Lunch will be provided. Attendees will be admitted on a first-come basis.

### Recognition and Treatment of Tardive Dyskinesia with a Focus on Older Populations

Elizabeth Elliott, PMHNP-BC

Studies have demonstrated that older adults receiving antipsychotics have a greater risk for tardive dyskinesia (TD), even when treated with lower doses for a shorter duration. This program will provide a brief overview of TD, including impact, burden, and risk implications, with a focus on older patients and residents receiving psychotropic medications. Learn suggested practices through a review of guidelines on TD monitoring, an overview of the abnormal involuntary movement scale exam, and video clips from experts on how they adapt TD assessment for non-ambulatory patients. Faculty will also present clinical data for an FDA-approved treatment option for adults with TD.

Please view our ad included with the electronic edition of the GAPNA Annual Conference program book on the GAPNA Event Page (www.gapna.org/live) and visit us at booth #304 in the Conference Exhibit Hall.

Sponsored by Neurocrine Continental, Inc.

#### 

Lunch will be provided. Attendees will be admitted on a first-come basis.

### Discover the Impact of GEMTESA, An Effective OAB Treatment: A Fresh Look at OAB Management in Long-Term Care Settings

Susann Varano, MD; Laurence Petty, MD, CMD

Over 30 million individuals over the age of 40 report OAB symptoms, yet it is largely undertreated. There is an unmet medical need in the medical management of OAB; there can be multiple barriers to care. The mainstay of OAB treatment is the class of anticholinergics; these medications are on the BEERS list and recently have become known for their associated risk of cognitive impairment, dementia, and AD. Vibergron, a beta-3-adrenergic agonist, is as equally efficacious as the anticholinergic class has a favorable safety profile.

### Sponsored by Urovant Sciences

### 1:40 pm – 2:40 pm Concurrent Sessions

141 Pulmonary Hypertension – AC, R ♥

(1.0 CH which includes 0.15 hours of pharmacology credit)

Melissa Kramps, DNP, GNP-BC, NP-C

**Learning outcome:** After completing this learning activity, the participant will be able to describe the management of pulmonary hypertension as a unique disease state in the older adult population.

### 142 Non-Infectious Systemic Inflammatory Response in the Elderly – R (1.0 CH which includes 0.25 hours of pharmacology credit)

Christine Collins, DNP, FNP-BC, APRN

**Learning outcome:** After completing this learning activity, the participant will be able to identify the affect of aging on the immune response and criteria for SIRS response, including distinguishing infectious vs. non-infectious origins of SIRS.

### 143 Mandatory Nursing Home Closure Impact on Resident Psychiatric Medication Usage − R

(1.0 CH which includes 0.5 hours of pharmacology credit)

Natalie Baker, DNP, CRNP, CNE, GS-C, FAANP, FAAN; Bethany Gilbert, DNP, CRNP,

Learning outcome: After completing this learning activity, the participant will be able to describe the impact of social isolation and loneliness on psychological health of long-term care residents.

2:50 pm - 3:50 pm Concurrent Session

151 Long-Term COVID - AC, R

(1.0 CH which includes 0.15 hours of pharmacology credit)

Kristine Anne Scordo, PhD, ACNP, ACNP, FAANP

Learning outcome: After completing this learning activity, the participant will be able to discuss the theoretical pathophysiology of post-COVID syndrome and discuss latest research in symptom management of patients with post-COVID syndrome.

### 152 Recognition and Management of Acute Gastrointestinal Diseases and Disorders Presenting in the Older Adult - R

(1.0 CH which includes 0.15 hours of pharmacology credit)

Anna Boone, PhD, ANP-BC

Learning outcome: After completing this learning activity, the participant will be able to identify signs and symptoms of acute gastrointestinal diseases in the older adults and describe appropriate treatment therapies according to guidelines.

### 153 Assessment of the Older Adult Driver in the Primary Care Setting 9 (1.0 CH)



Kanah Lewallen, DNP, AGPCNP-BC, GNP-BC; Jennifer Kim, DNP, GNP-BC, GS-C

Learning outcome: After completing this learning activity, the participant will be able to identify older adult patients who need to be screened for fitness to drive.

**Concurrent Sessions** 4:00 pm - 5:00 pm

161 The Stages of ARDS - AC. R 💇

(1.0 CH which includes 0.15 hours of pharmacology credit)

Deanna Adams, MSN, APRN, FNP-C, GS-C, AGACNP-BC, CEN

Learning outcome: After completing this learning activity, the participant will be able to identify the stages of ARDS and an evidence-based treatment plan for ARDS.

### 162 Better Brain? Dementia Prevention? Keys to Reducing Risk of Cognitive Decline

(1.0 CH)

Cindy Nissen, MSN, APN, CWCN

Learning outcome: After completing this learning activity, the participant will be able to create individualized brain health care plans using state-of-the-science strategies.

### 163 Engaging Techniques to Integrate Social Determinants of Health **Learning Activities into Practice and Academia** (1.0 CH)

Amanda Peacock, DNP, AGPCNP-C; Sara McCumber, DNP, APRN, CNP, CNS

Learning outcome: After completing this learning activity, the participant will be able to discuss the impact of social determinants of health on patient care and demonstrate activities to integrate SDOH into academic and clinical settings.

5:00 pm - 6:30 pm **Exhibits Open/Raffle Basket Auction** 

### Friday, September 16, 2022

6:00 am - 7:00 am Foundation Fun Run/Walk

6:30 am - 5:30 pm **Registration Open** 

#### 7:00 am - 8:00 am **Industry-Supported Presentation Theater**

Breakfast will be provided. Attendees will be admitted on a first-come basis.

### Managing Type 2 Diabetes in the Long-Term Care Setting

Moderator: Brandon Jerome, PharmD

Mark D. Corriere, MD, FACP

The management of diabetes in older adults should be individualized based on health status and living situation and should be simplified to achieve age-appropriate glycemic targets while minimizing risk of hypoglycemia. This program will discuss the impact of hypoglycemia, guideline recommendations on simplifying or intensifying insulin regimens, and the management of type 2 diabetes with for patients in LTC facilities, focusing on older adults.

### Sponsored by Sanofi General Medicines Medical Affairs

#### **General Session** 8:15 am - 9:15 am

210 The Role and Responsibility of the APRN For Effective Advocacy 9 (1.0 CH)



Donna Hamby, DNP, ACNP-BC, RN, DEGN; Kimberly Posey, PhD, DNP, APRN, AG-PCNP-BC, GS-C; Susan Mullaney, DNP, APRN, GNP-BC, GS-C, FAANP; Jennifer Kim, DNP, GNP-BC, GS-C; Christy Kroboth, MSN, RN, CRNP, ANP-BC; Cathy Brown, DNP, RN. CNS

**Learning outcome:** After completing this learning activity, the participant will be able to define health policy and advocacy and describe the APRN role in health policy and advocacy.

**Exhibits Open/Coffee Break/** 9:15 am - 10:45 am **Raffle Basket Auction** 

10:45 am - 11:45 am General Session 9

220 Fluid & Electrolytes

(1.0 CH)

John Gaillard, MD

**Learning outcome:** After completing this learning activity, the participant will be able to identify commons issues related to fluids and electrolytes in the treatment of the older adult patients.

### 12:00 pm – 1:00 pm Industry-Supported Presentation Theater

Lunch will be provided. Attendees will be admitted on a first-come basis.

### Considerations in Long-Term Care: Managing Hallucinations and Delusions in Residents with Parkinson's Disease Psychosis

Fay Bembry, FNP, PMHNP

This presentation theater will discuss educational information about hallucinations and delusions associated with Parkinson's disease (PD) psychosis, including the symptoms of PD psychosis, a non-motor aspect of PD; the impact and burden of PD psychosis on patient and their caregivers; the proposed role of serotonin, specifically 5-HT2A receptors, in PD psychosis; and the relevant treatment considerations when addressing PD psychosis.

Sponsored by Acadia Pharmaceuticals Inc.

### 12:00 pm – 1:00 pm Industry-Supported Presentation Theater

Lunch will be provided. Attendees will be admitted on a first-come basis.

### Managing Insomnia in Patients with Mild to Moderate Alzheimer's Disease

Sheldon H. Preskorn, MD

This presentation theater will discuss the burden of insomnia in insomnia patients with mild to moderate Alzheimer's disease, review the profile of an insomnia patient with mild to moderate Alzheimer's disease, and review an option to help manage insomnia.

#### Sponsored by Merck

### 1:15 pm - 2:15 pm Concurrent Sessions

### 231 Primary to Acute Care Atrial Fibrillation – AC, R

(1.0 CH which includes 0.5 hours of pharmacology credit)

Kristine Anne Scordo, PhD. ACNP. ACNP. FAANP

**Learning outcome:** After completing this learning activity, the participant will be able to discuss updates to the management of atrial fibrillation, including pharmacologic and non-pharmacologic options for treatment.

### 232 Movement Disorders - R 💇

(1.0 CH which includes 0.33 hours of pharmacology credit)

Patti Parker, PhD, APRN, CNS, AGNP-BC, GS-C

**Learning outcome:** After completing this learning activity, the participant will be able to describe typical and atypical presentations and treatments for common movement disorders.

### 233 What Matters? Lessons Learned by Advanced Practice Hospice and Palliative Care Nurses

(1.0 CH)

Annemarie Dowling-Castronovo, PhD, GNP-BC, ACHPN; Stacey Chapman, MSN, ANP-BC; Amy Imes, MSN, GNP-BC

**Learning outcome:** After completing this learning activity, the participant will be able to identify evidence-based resources to guide goals of care (GOC) conversations and list one way to improve communication with older adults and their families.

### 2:15 pm - 3:15 pm

Exhibits Open/Refreshment Break/
Prize Drawings/Raffle Basket Auction

### 3:15 pm - 4:15 pm Concurrent Sessions 241 Weight-Biased Attitudes in the Acute Care Setting - AC (1.0 CH)

Gregory Marler, DNP, APRN, ACNP, FCCP

**Learning outcome:** After completing this learning activity, the participant will be able to describe the impact of weight-biased attitudes on patients in the acute care setting.

### 242 HIV & Aging (1.0 CH)

Kara McGee, DMS, MSPH, PA-C, AAHIVS

**Learning outcome:** After completing this learning activity, the participant will be able to describe the impact of HIV on aging and the common medical comorbities in older adults living with HIV.

### 243 Preparing for a Pandemic: Two Perspectives (1.0 CH)

### NP Toolkit for Practicing in PA/LTC During Disasters and Infectious Disease Outbreaks

Patrick Luib, MSN, APRN-BC

**Learning outcome:** After completing this learning activity, the participant will be able to identify resources needed for practicing in post-acute and long-term care settings during disasters and infectious disease outbreaks.

### Disaster Preparedness for Vulnerable Older Adults: Are You Ready to Be Informed, Build a Kit, and Make a Plan?

J. Michelle Moccia, DNP, ANP-BC, GS-C

**Learning outcome:** After completing this learning activity, the participant will be able to ready their community for a potential disaster with attention to the vulnerable older adult population and those with disabilities.

### 4:15 pm – 5:30 pm GAPNA Gallery

Learn more about GAPNA's Committees and Special Interest Groups (SIGs) at this wine and cheese reception event.

### 5:30 pm – 6:45 pm Industry-Supported Presentation Theater(s)

Light refreshments will be provided. Attendees will be admitted on a first-come basis.

Defining Meaningful Benefits for Patients with Alzheimer's Disease: Timely Diagnosis, the Role of Biomarkers, and Interpreting Treatment Outcomes

Malaz Boustani, MD

This presentation theater will dive deep into what matters most to patients and caregivers at each stage in the Alzheimer's disease treatment pathway. Topics will highlight the challenges of timely diagnosis and considerations for early detection of symptoms. The importance of using biomarkers in diagnosis and management will be explored along with the best way to communicate the need for biomarker confirmation to patients and caregivers. Discussion will close with interpreting treatment outcomes and identifying what matters most to patients and their care partners.

Sponsored by Eisai Inc.

### Saturday, September 17, 2022

6:30 am – 4:00 pm Registration Open

8:15 am − 9:15 am General Session ©
310 Sexual Health in the Aging Population
(1.0 CH)

Heather Quaile, DNP, WHNP-BC, AFN-C, CSC, IF, FAANP

**Learning outcome:** After completing this learning activity, the participant will be able to identify myths about sexuality in the aging population and identify ways to assess and promote the sexual health of older adults.

9:30 am - 11:30 am In-Depth Focus Sessions 321 Project Podium Presentations (2.0 CH)

- Project 1: Perceived Effectiveness of Nursing Faculty of Clinical Video Simulation for Use in Nurse Practitioner Education
  Laurie Kennedy-Malone, PhD, GNP-BC, FAANP, FGSA
- Project 2: Highlights from the 8<sup>th</sup> Edition of the Gerontology Resources for APRN Preceptors and Students Toolkit

  Melissa Kramps, DNP, GNP-BC, NP-C
- Project 3: Academic Needs Assessment: Examining Post-Licensure
  Nursing Students Perceived Assessment and Reporting Elder
  Abuse Knowledge
  Sally Mahmoud, DNP, MSN/MPH, RN, CNE
- Project 4: Implementation of an Age-Friendly Health System MinuteClinic DNP Fellowship
  Holly Kouts, MSN, MBA, FNP; Heba Aldossary, PhDc, MSN, BN
  (Hons), RN
- Project 5: Quality of Care in Nursing Homes: A Consensus Report of the National Academies of Sciences, Engineering, and Medicine Gregory Alexander, PhD, RN, FAAN, FACMI, FIAHSI
- Project 6: Thinking Outside the Classroom: Development of an Interactive Pressure Injury Prevention Fair Notably of Older Adults Risk for Undergraduate and Graduate Nursing Students Autumn Henson, DNP, APRN, GNP-BC, WCC

**Learning outcome:** After completing this learning activity, the participant will be able to identify the key findings of each presentation and discuss the limitations and implications for future practice.

#### **Session Key**

Look for these codes to find sessions and activities offering extra education support to GAPNA Conference attendees.

### 

based on the UCLA Alzheimer's and Dementia Care Program (2.0 CH which includes 0.5 hours of pharmacology credit)

Moderator: Leslie Evertson, DNP, GNP-BC, RN

Presenters: Michelle Panlilio, DNP, GNP; Jennifer Serafin, MS, BSN, GNP-BC, GS-C

**Learning outcome:** After completing this learning activity, the participant will be able to discuss issues related to dementia in the older adult population.

### 323 Helping Older Adults Live the Sweet Life: Incorporation of Techniques and Technology – R

(2.0 CH which includes 0.5 hours of pharmacology credit)

Michelle Talley, PhD, ACNP-BC, FAANP, FNAP

**Learning outcome:** After completing this learning activity, the participant will be able to identify at least three evidence-based ways to provide safe and effective patient-centered care for older adults with diabetes.

### 11:45 am - 1:30 pm

### 330 Membership Meeting & Awards Luncheon

Presidents Welcome and Business Meeting - Natalie Baker

Foundation Awards Presentation – Jennifer Serafin

GAPNA Podium and Poster Award Presentations – Tomika Williams and Sara McCumber

GAPNA Awards for Excellence Presentation - Brette Svensson

Closing Remarks and Passing of Gavel - Natalie Baker

Incoming President Remarks - Jennifer Kim

Adjournment - Jennifer Kim

(see pages 15-18 for award winners)

### 1:45 pm – 2:45 pm Concurrent Sessions (1.0 CH) 341OD Heparin-Induced Thrombocytopenia – AC

(1.0 CH)

Peter Miller, MD

**Learning outcome:** After completing this learning activity, the participant will be able to identify the different types and presentation of HIT as well as appropriate treatment strategies.

Session cancelled for live onsite presentation. On-demand recording will be available for all registered attendees via the GAPNA Conference Event Page.

### Navigating Polypharmacy in the Older Adult: Best Practices and De-Prescribing Recommendations – №

(1.0 CH which includes 1.0 hour of pharmacology credit)

Shantha Franks, DNP, RN, APN, GNP-BC, NP-C; Margaret Hurvk, DNP, APN-C

**Learning outcome:** After completing this learning activity, the participant will be able to describe the scope and impact of polypharmacy for older adults and describe evidence-based approaches to assist in de-prescribing.

### 343 Improving Clinical Practice on Social Isolation and Loneliness in Older Adults

(1.0 CH)

Sara McCumber, DNP, APRN, CNP, CNS; Tamatha Arms, DNP, PhD, NP-C, PMHNP-BC; Tina Marie Baxter. APRN. GNP-BC

**Learning outcome:** After completing this learning activity, the participant will be able to differentiate between social isolation and loneliness and evaluate the APRN role in recognizing SI and loneliness as a SDoH.

3:00 pm - 4:00 pm General Session

350 Care-Resistant Behaviors in Older Adults Living with Dementia: Prevention and Management − R ♀

(1.0 CH which includes 0.25 hours of pharmacology credit)

Rita Jablonski, PhD, CRNP, FGSA, FAAN

**Learning outcome:** After completing this learning activity, the participant will be able to describe differences between true refusal and refusals based on fear and list three ways to prevent and manage care refusal behavior.

### **2022 Annual Conference Planning Committee**

Michele Talley, PhD, ACNP-BC, FAANP, FNAP, Chair
Patti Parker, PhD, APRN, CNS, AGNP-BC, GS-C, Chair-Elect
Amy Imes, MSN, GNP-BC
Ron Ordona, DNP, FNP-BC
Leslie Chang Evertson, DNP, RN, GNP-BC
Rosalind Caumban, DNP, AGNP-C
Margaret Bowers, DNP, RN, FNP-BC, FAANP, FAAN, Board Liaison
Rosemarie Marmion, MSN, RN, NPD-BC, NE-BC, Education Director

### 2022 Annual Conference Research and Education Committee Abstract Reviewers

Kala Blakely, DNP, CRNP, NP-C, CNE, FAANP Kanah Lewallen, DNP, AGPCNP-BC, GNP-BC Margaret Bowers, DNP, RN, FNP-BC, Sara McCumber, DNP, APRN, CNP, CNS

FAANP, FAAN
haron Bronner DNP MSN ACHPN GNP

Sharon Bronner, DNP, MSN, ACHPN, GNP-BC Jean Burnkrant, DNP, AGNP-BC

Mary DiGiulio, DNP, ANP-BC, GNP-BC, FAANP Vaunette Fay, PhD, APRN, GRN-BC, FNP Erica Frechman, PhD, AGPCNP-BC, ACHPN,

NEA-BC, FPCN

MJ Henderson, MS, RN, GNP-BC (retired) Kelly Henrichs, DNP, RN, GNP

Autumn Henson, DNP, APRN, GNP-BC, WCC Laurie Kennedy-Malone, PhD, GNP, FAANP, FGSA

Catharine Kopac, PhD, RN, GNP-BC Melissa Kramps, DNP, GNP-BC, NP-C Sara McCumber, DNP, APRN, CNP, CNS Karen Melillo, PhD, A-GNP-C, FAANP, FGSA Joanne Miller, PhD, APRN/GNP-BC Renee Mirovsky, DNP, RN, ANP-BC J. Michelle Moccia, DNP, ANP-BC, GS-C Fiona Okoroti, DNP, APRN, AGPCNP-BC,

PMHNP-BC Amanda Peacock, DNP, AGPCNP-C Ju Young Shin, PhD, APRN, ANP-C Laura Sutherland, DNP, AGPCNP

Ladsine Taylor, MSN, APRN, GNP-BC, CDP Carla Tozer, DNP, AGPCNP-BC, FPA-APRN/CNP

Tomika Williams, PhD, AGNP-C, CDP Joshua Zucker, DNP, FNP-BC, GNP-C

### **Foundation Awards**

Awards will be presented live during session 330: Membership Meeting and Awards Luncheon on September 17, 2022, from 11:45 am - 1:30 pm ET.

### **GAPNA Foundation Award (\$2,000 each)**

Focuses on improving care for older adults.

The 2022 Awardee for the GAPNA Foundation Grant is: Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA: "Factors Associated with Unplanned 30-day Readmissions in the Older Adult with Cancer: A Comprehensive Cancer Center Exploratory Improvement Project"

**The 2022 awardee for the GAPNA Founation grant is:** Dr. Connie S. Cole, PhD, DNP, RN-BC, NP-C: "Understanding Provider Perspectives about the Use of Palliative Care Referral Criteria or Tools with Nursing Facility Residents"

### GAPNA Foundation Research/Clinical Project Grant Award (\$2,000 each)

The Research/Clinical Project Grants fund a proposed research project and a clinical project that improve health outcomes for older adults.

**The 2022 Awardee for Research is:** Ms. Katherine Ladetto, MSN, ANP/GNP; "Long-term Care Nurses' Intent to Stay: A Qualitative Hermeneutic Phenomenology Study"

**The 2022 Awardee for Clinical Projects is:** Dr. Candace C. Harrington, PhD, DNP, APRN, AGPCNP-BC, CNE: "Exploring Cognitive Impairments' Impact on Residents' Heart Failure Burden"

### Virginia Lee Cora Research Grant (\$2,000)

This grant was established in memoriam to Dr. Virginia Lee Cora, a founding member of the GAPNA Foundation. Focus is APRNs working with older adults and their families (including non-traditional family).

The 2022 awardee for the Virginia Lee Cora Research Grant is: Dr. Mariya Kovaleva, PhD, RN, AGPCNP-BC: "Telehealth Transitional Care for Persons Living with Dementia: A Feasibility Study"

### Barbara Resnick Health Promotion Grant (\$2,000)

This grant is funded by a generous donation from Dr. Barbara Resnick. Focus on health promotion for older adults.

**The 2022 awardee for Barbara Resnick Health Promotion Grant is:** Dr. Katelyn E. Webster, PhD, RN: "Factors Influencing Changes in Disability Outcomes and Transfers to Nursing Home Among Assisted Living Residents with Diabetes"

### **Foundation Awards**

### Dave Butler Spirit of GAPNA Award (\$1,000)

David H. Butler, Vice President for Johnson & Johnson USA, was a strong advocate and supporter of the goals and mission of GAPNA. This award, given in his honor, is awarded by the Foundation to a GAPNA member who demonstrates an outstanding commitment to the mission and goals of our organization.

**The 2022 Awardee is:** Dr. Laurie Kennedy-Malone, PhD, GNP-BC, FAANP, FGSA, FAGHE

### AMDA Foundation Futures Educational Grant (\$2,000)

This awardee receives admission to the AMDA Foundation Futures Program at the AMDA Annual Conference, AMDA membership for one year, and access to the AMDA Mentoring Program.

The 2022 Awardee is: Dr. Rebecca Waksmunski, DNP, AGNP-C

### **GAPNA Podium and Poster Awards**

### (Funded by the GAPNA Foundation)

### **GAPNA Podium Award Presentation**

The GAPNA Foundation Podium Award is provided to a short podium presentation as reviewed and selected by members of the GAPNA Research and Education Committees. Award selection is based on interest to advanced practice nursing, contribution to the care of older adults, clarity, and content.

The 2022 Awardee will be announced during the Membership Meeting and Awards Luncheon based upon onsite judging of content. The award will be presented live during the Membership Meeting and Awards Luncheon.

### **GAPNA Poster Award Presentation**

The GAPNA Foundation Poster Award is provided to a poster presentation as reviewed and selected by members of the GAPNA Research and Education Committees. Award selection is based on interest to advanced practice nursing, contribution to the care of older adults, clarity, and content.

The 2022 Awardee will be announced during the Membership Meeting and Awards Luncheon based upon virtual judging of content. The award will be presented live during the Membership Meeting and Awards Luncheon.

### **GAPNA** Awards for Excellence

Awards will be presented live during session 330: Membership Meeting and Awards Luncheon on September 17, 2022, from 11:45 am - 1:30 pm ET.

### **Innovative Project Excellence Award**

The GAPNA Innovative Project Award is given to a Committee or Special Interest Group (SIG) that exemplifies GAPNA's mission to enhance and promote the care of older adults. The Committee or SIG should demonstrate, through the use of gerontological nursing principles, outstanding innovative projects or initiatives to benefit GAPNA membership, gerontological advanced practice nursing, and/or care of older adults.

The 2022 Winner is: The GAPNA Historical Committee

### **Chapter Excellence Award**

The Established Chapter Excellence Award honors a chapter that best promotes the goals of the Gerontological Advanced Practice Nurses Association (GAPNA) through its member relationships, professional activities, and promotion of advanced practice gerontological nursing throughout the local, regional, and/or state during the past year.

The 2022 Winner: The GAPNA Liberty Chapter

### **Excellence in Community Service**

This award for outstanding community service is for an individual who demonstrates a commitment to service to the community. This commitment is demonstrated through the development or participation in programs that go well beyond the traditional service role of their profession. The award highlights community service as an important element of the mission of nursing professionals and singles out individuals who serve as examples of social responsiveness on the part of the nursing community

The 2022 Winner is: Jade Vergara, AGPCNP-C, NP

#### **Excellence in Clinical Practice**

This award for outstanding clinical practice is for an individual who demonstrates a commitment to geriatric clinical practice. This award acknowledges an individual who demonstrates, through the use of geriatric principles, outstanding geriatric care that goes well beyond the traditional service role of their profession. The award highlights clinical practice as an important element of the mission of nursing professionals and singles out individuals who serve as examples of geriatric expertise.

The 2022 Winner is: Margaret Huryk, DNP, APN, AGPCNP-BC

### **GAPNA** Awards for Excellence

#### **Excellence in Education**

The award for excellence in education recognizes an individual involved in the teaching and/or design of gerontological nurse practitioner curriculum or course content. The faculty member will demonstrate knowledge of the care of older adults and the ability to translate that knowledge to enhance students' understanding in innovative ways. The faculty member will encourage and inspire advanced practice students to develop their excellence in gerontology. In addition to excellence in teaching, the faculty member will exhibit excellence in practice and service to the community.

The 2022 Winner is: Sara McCumber, DNP, RN, CNP, CNS

### **Excellence in Leadership**

This award for outstanding leadership is for an individual who demonstrates a commitment to geriatrics through direct care, education and/or research. This award is for an individual who demonstrates the tenacity to advocate, through a variety of means, for geriatric education and care in a variety of settings that goes well beyond the traditional service role of their profession. The award highlights leadership as an important element of the mission of nursing professionals and singles out individuals who serve as examples of geriatric expertise.

The 2022 Winner is: Cassandra Vonnes, GNP

#### **Excellence in Research**

This award for research is for an individual who demonstrates a commitment to research in nursing that benefits the geriatric community. This commitment is demonstrated through the development or participation in research projects that emphasize or go beyond the traditional service role of their profession. The award highlights research as an important element of the mission of nursing professionals and singles out individuals who serve as examples of nursing scientists within the nursing community.

The 2022 Winner is: Sabrina Pickens, PhD, RN, ANP-BC, GNP-BC

### **Health Affairs Scholarship Winners**

This scholarship provides assistance to a GAPNA member who wishes to attend the annual American Association of Nurse Practitioners (AANP) Health Policy Conference.

The 2022 Winner is: Abby Luck Parish, DNP, APN-BC



## **Preparing the Next Generation of Leaders in Gerontological Nursing**

The **GAPNA Leadership Institute** is a leadership development program designed exclusively for GAPNA members and organizational affiliates who aspire to lead excellence in the care of older adults.

The Leadership Institute is an 18-month mentored program for a select group of advanced practice nurse emerging leaders. Leadership fellows participate in a monthly small group learning collaborative. The program includes both online synchronous and face-to-face components. Each fellow is paired with a GAPNA leader who provides one on one mentorship, guidance and support throughout the year. Fellows complete an approved project that advances excellence in care of older adults.

In this program, fellows advance their leadership skills, gain a deeper understanding of GAPNA's organizational infrastructure, and learn how professional organizations function to advance APRN practice and excellence in the care of older adults.

We invite you to congratulate the 2022 GAPNA Leadership Institute Fellows pictured here.

View poster displays highlighting the work of the 2022 GAPNA Leadership Institute Fellows onsite and virtually via the Conference Event Page. A list of these posters is included on page 31.

### 2022 GAPNA Leadership Institute Fellows



Kala Blakely, DNP, CRNP, NP-C, CNE, FAANP



Victoria (Vycki) Nalls, PhD, CRNP, ACHPN, CWS



Tamatha Arms, DNP, PhD, NP-C, PMHNP-BC



Brenda Van Roosenbeek, NP

### **2022 Strategic Partners**

## GAPNA would like to thank the following organizations for their support:

**Strategic Partners - Platinum Level** 





### **Strategic Partner - Gold Level**



### **Strategic Partners**





### 2022 Program-At-A-Glance

### All times: Eastern Time (ET)

### Wednesday, September 14, 2022

7:00 am - 7:00 pm: Registration Open

Location: Registration Area #1

8:00 am - 4:30 pm: Pre-Con Workshop

010: GS-C Exam Review Workshop

Location: Poinciana A

8:00 am - 11:30 am: Pre-Con Workshop

**020:** Suturing Workshop **Location:** Grand Cypress C

12:00 pm - 5:00 pm: Pre-Con Workshop

**030:** Pharmacology Workshop **Location:** Grand Cypress A

**12:30 pm: Foundation Golf Outing Location:** Offsite (Villas of Grand Cypress)

### Thursday, September 15, 2022

6:30 am – 5:30 pm: Registration Open Location: Registration Area #1

7:00 am – 8:00 am: Presentation Theater Smith & Nephew: Debridement with Collagenase SANTYL♦ Ointment

**Location:** Grand Cypress G

8:00 am - 8:15 am: Welcome/Introduction Location: Grand Cypress D

**8:15 am – 9:15 am: Keynote Address 120:** Full Practice Authority Framing *Location: Grand Cypress D* 

9:15 am – 10:45 am: Grand Opening Exhibit Hall/Coffee Break/Raffle Basket Auction

Location: Regency Hall

10:45 am – 12:15 pm: Highlighted Session

130: Resiliency Across Roles & Settings

**Location:** Grand Cypress D

12:30 pm – 1:30 pm: Presentation

**Theaters** 

**Urovant: The Impact of GEMTESA** 

Location: Grand Cypress G

Neurocrine Biosciences: Recognition &

**Treatment of Tardive Dyskinesia Location:** Grand Cypress A

1:40 pm - 2:40 pm: Concurrent Sessions

**141:** Pulmonary Hypertension *Location: Grand Cypress D* 

**142:** Non-Infectious Systemic Inflammatory

Response in Elderly **Location:** Windsong 2

**143:** Mandatory Nursing Home Closure Impact on Resident Psychiatric Medication

Usage

Location: Windsong 4

2:50 pm - 3:50 pm: Concurrent Sessions

**151:** Long-Term COVID **Location:** Windsong 2

**152:** Acute Gastrointestinal Diseases & Disorders Presenting in Older Adult

Location: Windsong 4

153: Assessment of Older Adult Driver in

Primary Care Setting

Location: Grand Cypress D

4:00 pm - 5:00 pm: Concurrent Sessions

**161:** The Stages of ARDS **Location: Grand Cypress D** 

**162:** Keys to Reducing Risk of Cognitive

Decline

Location: Windsong 2

**163:** Integrate Social Determinants of Health Learning Activities into Practice & Academia

Location: Windsong 4

5:00 pm - 6:30 pm: Exhibits Open/

Raffle Basket Auction Location: Regency Hall

### 2022 Program-At-A-Glance

### Friday, September 16, 2022

6:00 am - 7:00 am: Foundation Fun

Run/Walk

**Location:** Outside Resort (Meet in Lobby)

6:30 am - 5:30 pm: Registration Open

Location: Registration Area #1

7:00 am - 8:00 am: Presentation Theater

Sanofi: Type 2 Diabetes in the LTC

Setting

Location: Grand Cypress G

8:15 am - 9:15 am: General Session

210: Role & Responsibility of APRN for

Effective Advocacy

Location: Grand Cypress D

9:15 am - 10:45 am: Exhibits Open/Coffee Break/Raffle Basket

Auction

Location: Regency Hall

10:45 am - 11:45 am: General Session

**220:** Fluid & Electrolytes **Location: Grand Cypress D** 

12:00 pm - 1:00 pm: Presentation

**Theaters** 

Acadia: LTC Hallucinations and

**Delusions in Residents with Parkinson's** 

Location: Grand Cypress A

Merck: Insomnia in Patients with Mild to

Moderate Alzheimer's Disease Location: Grand Cypress G

1:15 pm - 2:15 pm: Concurrent Sessions

231: Primary to Acute Care Atrial Fibrillation

**Location:** Windsong 2 **232:** Movement Disorders

Location: Grand Cypress D

233: Lessons Learned by Advanced Practice

Hospice & Palliative Care Nurses

Location: Windsong 4

2:15 pm – 3:15 pm: Exhibits Open/Refreshment Break/

Prize Drawings/Raffle Basket Auction

Location: Regency Hall

3:15 pm - 4:15 pm: Concurrent Sessions

**241:** Weight-Biased Attitudes **Location:** Windsong 2

**242:** HIV & Aging **Location:** Windsona 4

243: Preparing for Pandemic: 2 Perspectives

**Location:** Grand Cypress D

4:15 pm - 5:30 pm: GAPNA Gallery

Location: Portico West

5:30 pm - 6:45 pm: Presentation Theater

**Eisai: Benefits for Patients with** 

Alzheimer's Disease Location: Grand Cypress G

### Saturday, September 17, 2022

6:30 am – 4:00 pm: Registration Open

Location: Registration Area #1

8:15 am - 9:15 am: General Session

**310:** Sexual Health in Aging Population

**Location:** Grand Cypress D

9:30 am - 11:30 am: In-Depth Focus Sessions

**321:** Project Podium Presentations

Location: Windsong 2

**322:** Next Level Dementia Care **Location:** Grand Cypress A

323: Helping Older Adults Live the Sweet Life

Location: Windsong 4

11:45 am - 1:30 pm

**330:** Membership Meeting/Awards

Luncheon .....

Location: Grand Cypress D

1:45 pm - 2:45 pm: Concurrent Sessions

341: Heparin-Induced Thrombocytopenia

**Location:** Windsong 2

**342:** Polypharmacy in Older Adult

**Location:** Grand Cypress A

**343:** Improving Clinical Practice on Social Isolation & Loneliness in Older Adults

Location: Windsong 4

3:00 pm - 4:00 pm: General Session

350: Care-Resistant Behaviors in Older

Adults Living with Dementia **Location:** Grand Cypress D

### **2022 Conference Sponsors**





### **Companies Providing Industry-Supported Presentation Theaters**











Medical Education



### **Hyatt Regency Grand Cypress**

#### FLOOR PLAN Convention Level



Note: \* La Coquina Entrance on lobby level

### **Hyatt Regency Grand Cypress**

#### FLOOR PLAN Convention Level



## Nursing Continuing Professional Development and Disclosure Information

### **Conference Learning Outcome**

80% of APNs attending this conference will report via the conference evaluation that they intend to change their practice related to their enhanced knowledge about caring for older adults.

#### **Requirements for Successful Completion**

Attend 90% of each session in which contact hours are earned, complete an online evaluation, and submit.

#### **Disclosures**

**Abstract Reviewers:** No abstract reviewer reported an actual or potential financial relationship in relation to this nursing continuing professional development activity.

**Planning Committee Members:** No planning committee member reported an actual or potential financial relationship in relation to this nursing continuing professional development activity.

### Speakers

- Gregory Alexander (session 321) discloses that he serves as a research principal investigator for the Agency for Healthcare Research and Quality.
- Tamatha Arms (session 163) discloses that she received compensation for presenting for Pesi.
- Shantha Franks (session 342) discloses that she serves as a subject matter expert for nurse practitioner test bank on McGraw-Hill's digital platform, Access APN.
- Margaret Huryk (session 342) discloses that she serves as a subject matter expert for the ECHO project on dementia for the Joint Commission.
- Rita Jablonski (session 350) discloses that she is the owner of DementiaCentric Solutions, LLC.

- Sara McCumber (session 163, 343) discloses that she received HRSA ANEW grant funding for curriculum development.
- Michelle Panlilio (session 322) discloses that she serves as a consultant for Biogen Biotechnical Company and Eisai Pharmaceutical Company.
- Amanda Peacock (session 163) discloses that she received funding through HRSA ANEW grant for development of her simulation.
- Maria Shirey (session 130) discloses that she serves as editor-in-chief, Journal for Healthcare Quality, for the National Association for Healthcare Quality.

### Poster Presenters

Sally Mahmoud (poster P16) discloses that she received a 3-units course release grant (RSCA) from California State University Dominguez Hills which ended in the fall 2021 term.

### Commercial Support and Sponsorship Disclosure

This program received no commercial support or corporate sponsorship.

#### **Accreditation Statement**

This educational activity is jointly provided by Anthony J. Jannetti, Inc. (AJJ) and the Gerontological Advanced Practice Nurses Association (GAPNA).

Anthony J Jannetti, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Anthony J. Jannetti, Inc. is a provider approved by the California Board of Registered Nursing, Provider Number CEP5387.




## 2022 Annual Conference

September 15-17, 2022

Preconference Workshops on September 14<sup>th</sup>







Click on the *Live Sessions* tab, and then *Onsite Panel* to chat with other attendees, participate in polling questions (if applicable), and access other resources. Engaging this way will help you earn badges on our Leaderboard Challenge.

Visit *gapna.org/LIVE* to access handouts, complete Nursing Continuing Professional Development (NCPD) contact hour evaluations, and more.

Evaluation Deadline Date
October 31, 2022



### Poster Presentations

### **2022 GAPNA Annual Conference**

### **Nursing Continuing Professional Development Poster Presentations**

### 0.5 contact hours will be awarded for poster viewing.

Posters will be available for viewing in the Portico area across from Registration throughout the conference. Designated presenters will be in attendance with posters to answer questions during the below-listed times.

**Group A:** Thursday, September 15, 2022, 9:15 am – 10:45 am ET **Group B:** Thursday, September 15, 2022, 5:00 pm – 6:30 pm ET **Group C:** Friday, September 16, 2022, 9:15 am – 10:45 am ET

**Poster session learning outcome:** After completing this learning activity, the participant will be able to assess innovations being used by other professionals in the specialty and evaluate the potential of implementing the improvements into practice.

### **Group A**

P01: Improving Fall Rates Among Older Adults in the Long-Term Care Setting: Implementation of an Educational Fall Prevention-Based Toolkit into New Employee Orientation

Jamilah Middlebrooks, DNP, Registered Nurse, Atlanta VA Medical Center, Decatur, GA

Virtual-only poster. Please view via the GAPNA Conference Event Page.

P02: Creating WOC Interventions in Response to Age-Related Barriers to Ostomy Independence and Self-Care

Ruth Ann Pendergrast, MSN, RN, AGPCNP-C, CWON, Ostomy Nurse Practitioner, Beaumont Health, Royal Oak, MI

Virtual-only poster. Please view via the GAPNA Conference Event Page.

P03: Factors Associated with Participation Willingness of Time Banking Among Older People with Chronic Diseases in Community

Qianqian Du, MS, Student, Sun Yat-sen University, Guangzhou, Guangdong, China

Virtual-only poster. Please view via the GAPNA Conference Event Page.

P04: The Effect of COVID-19 Quarantine on Body Weight in Residents of Assisted-Living Facilities

Maureen Beck, DNP, APRN, GNP-BC, Assistant Professor, McGovern Medical School at UTHealth, Houston, TX Shuyan Bi, AANP, Nurse Practitioner, UT Physicians, Houston, TX

P05: Pharmacogenomic Data: A Useful Tool in Geriatric Medication Safety

Angela Scardina, DNP, RN, APRN, Director, APRN Programs, University of Toledo, College of Nursing, Toledo, OH

Kelly Magrum, MSN, RN, FNP-C, Nurse Practitioner, Promedica Integrated Medical Management, Toledo, OH

### Poster Presentations

### P06: Examining the Impact of the Covid-19 Pandemic on the Mental Health on Chronic Disease in Elderly Populations

Susan Bushinski, DNP, RN, ACNP-BC, FNP-BC, Associate Professor of Nursing, Eastern Michigan University, Ypsilanti, MI

### **Group B**

### P07: Diagnosis of Peripheral Arterial Disease in the Older Adult

Tiffany Street, DNP, ACNP-BC, Associate Nursing Officer, Vanderbilt University School of Nursing, Nashville, TN

Virtual-only poster. Please view via the GAPNA Conference Event Page.

### P08: Atypical Presentation of Illness in the Older Adult: Case Studies in Support of Zebras

Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, NICHE Coordinator, Moffitt Cancer Center, Tampa, FL

### P09: Cardiovascular Risk Assessment in the Older Adult: Don't Call It Cardiac Clearance!

Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, NICHE Coordinator, Moffitt Cancer Center, Tampa, FL

### P10: Classroom Interactive Dementia Simulation: Strengthening AGPCNP Students' Knowledge of Dementia Through Sensory Simulation

Kathryn Lawrence, DNP, ANP, AACC, Adult/Gerontological Nurse Practitioner, University of North Carolina Greensboro, Greensboro, NC

Autumn Henson, DNP, APRN, GNP-BC, WCC, Assistant Clinical Professor and Concentration Coordinator, University of North Carolina, Greensboro, NC; Gerontological Nurse Practitioner and Wound Care Consultant, Physicians Eldercare, Winston-Salem, NC

### P11: Care-CO-ordination and eMpowerment of Patients in Systems-to-Systems Transitions (COMPASS program): Implementation and Outcomes of Transitions of Management of Care Using a Client-Centered and Fiscally Responsible Approach

Georgia BrinitStiffler, DNP, MSN, AG-ACNP-BC, Nurse Practitioner, Veteran Healthcare Administration, Pittsburgh, PA

### P12: Disaster Preparedness: Considerations for Our Older Patient Population

Mary DiGiulio, DNP, ANP-BC, GNP-BC, FAANP, Associate Chair for Graduate Nursing and Director of DNP and NP Programs, Moravian University, Bethlehem, PA

Sherri Rivera, DNP, APRN, ANP-C, FNKF, Assistant Professor of Clinical Nursing, Louisiana State University Health New Orleans School of Nursing, New Orleans, LA

### **Poster Presentations**

### **Group C**

- P13: Tell Me More A Stepwise Approach to Meaningful Conversations **Resulting in Goal Concordant Care** 
  - Anna Go, APRN, ANP-BC, Optum, Hartford, CT

P17:

- P14: Climate Change Effects on the Older Adult Ann Marie Kriebel-Gasparro, DrNP, FNP, GNP, Walden University, Minneapolis, MN
- P15: Does Sex Matter in Healthy Aging? Ann Marie Kriebel-Gasparro, DrNP, FNP, GNP, Walden University, Minneapolis, MN
- P16: Examining Indicators and Barriers to Assessing and Reporting Elder **Abuse Among Post-Licensure Nursing Students** Sally Mahmoud, DNP, MSN/MPH, RN, CNE, Assistant Professor, California State University Dominguez Hills, Canton, CA
- **Emotional Distress Among Older Adults During the COVID-19 Pandemic: An Integrative Review** Keisha Lovence, DNP, RN, ACNP-BC, Associate Professor, Eastern Michigan University, Ypsilanti, MI



## Non-Nursing Continuing Professional Development Poster Presentations

No contact hours are awarded for viewing these posters.

Posters will be available for viewing in the Portico area across from Registration throughout the conference.

Non-NCPD01: Long-Term Valbenazine Is Effective for Tardive Dyskinesia in Elderly Patients (≥65 Years)

Amy Belnap, MSN, APRN, PMHNP-BC, Clinical Practice Liaison, Neurocrine Biosciences, Inc., San Diego, CA

Non-NCPD02: Efficacy and Safety of Once-Daily Opicapone in Older Patients with Parkinson's Disease and Motor Fluctuations

Amy Belnap, MSN, APRN, PMHNP-BC, Clinical Practice Liaison, Neurocrine Biosciences, Inc., San Diego, CA

Non-NCPD03: Utilization of Home Nursing to Mitigate the Impact of COVID-19 on the Conduct of the Gantenerumab GRADUATE Trials

Jilli Johnson, MSN, RN, Medical Science Liaison, Genentech, Portland, OR

### **GAPNA Leadership Institue Poster Presentations**

GLI 1: To Screen or Not to Screen When Loneliness Is in Question

Kala Blakely, DNP, CRNP, NP-C, CNE, FAANP, Assistant Professor, University of Alabama at Birmingham School of Nursing, Birmingham, AL

Virtual-only poster. Please view via the GAPNA Conference Event Page.

**GLI 2: Wound Care: A Crash Course for the Geriatric Provider** 

Victoria Nalls, PhD, CRNP, ACHPN, CWS, Director of Clinical Training and Development, Aledade Care Solutions, Bethesda, MD

**GLI 3: Gerontology Resources for Managing Mental Health Among Older Adults Across Care Settings: A Toolkit for Nurse Practitioner Providers** 

Tamatha Arms, DNP, PhD, NP-C, PMHNP-BC, Associate Professor, University of North Carolina Wilmington, Wilmington, NC

**GLI 4: The Impact Nurse Practitioner (NP) Outreach and Education Has on Increasing NP Student Membership in National Nursing Organizations** Brenda Van Roosenbeek, NP, Lead Clinical Team Manager for Northeast Region, UnitedHealth Group Optum, North Prairie, WI

- Ask a practice question
- Share your gerontological resources
- Follow local Chapter News
  - Join a Committee/
     Special Interest Group
  - Connect with your peers
  - Review the GAPNA Daily Digest and keep up with conversations

And more...

### Available on...




GAPNA Exchange Open Forum is available to all GAPNA members.

gapna.org/exchange

### **Exhibit Hall Floor Plan**

### **Hyatt Regency Grand Cypress**

### **Regency Hall**



### **2022 Exhibitor Listing**

#### Acadia Pharmaceuticals, Inc. - Booth #106

12830 El Camino Real, Suite #400 San Diego, CA 92130 www.acadia-pharm.com

### Alzheimer's and Dementia Care Program – Booth #321

10945 Le Conte Ave, Suite 2339 Los Angeles, CA 90095 www.adcprogram.org

### American Nurses Credentialing Center - Booth #217

8515 Georgia Avenue Suite 400 Silver Spring, MD 20910 www.nursingworld.org/ANCC

### Avanir Pharmaceuticals, Inc. - Booth #101

30 Enterprise Drive, Suite 200 Aliso Viejo, CA 92656 www.ayanir.com

#### AztraZeneca - Booth #117

1800 Concord Pike Wilmington, DE 19897

### Boehringer Ingelheim Pharmaceuticals, Inc. – Booth #111

5138 Deerview Park Drive Cleves, OH 45002 www.boehringer-ingelheim.com

#### CMP Pharma - Booth #319

8026 US-264 Farmville, NC 27828 www.cmppharma.com

#### Dispatch Health - Booth #316

3825 Lafayette Street Denver, CO 80205 www.dispatchhealth.com/careers

### Edenbridge Pharmaceuticals, LLC – Booth #210

169 Lackawanna Avenue, Suite 110 Parsippany, NJ 07054 www.dartislahcp.com

#### **GAPNA Foundation - Booth #311**

East Holly Avenue, Box 56 Pitman, NJ 08071 www.gapna.org/about/foundation

### GAPNA Membership - Booth #303

East Holly Avenue, Box 56 Pitman, NJ 08071 www.gapna.org

### Genentech USA, Inc. - Booth #107

1 DNA Way South San Francisco, CA 94080 www.gene.com

#### The Gideons International - Booth #318

PO Box 140800 Nashville, TN 37214 www.gideons.org

### Home Instead - Booth # 118

13323 California Street Omaha, NE 68130 homeinstead.com

### IDgenentix - Booth #113

505 S Friendswood Drive, Suite 401 Friendswood, TX 77546 www.castlebiosciences.com

### Lilly USA - Booth 110

Lilly Corporate Center Indianapolis, IN 46285

#### MedTech International Group – Booth #306

21175 State Highway 249 Houston, TX 77070 www.medtechinternationalgroup.com

#### Merck & Co., Inc. - Booth #201

2000 Galloping Hill Road Kenilworth, NJ 07033

### Neurocrine Biosciences, Inc. – Booth #304

12780 El Camino Real San Diego, CA 92130 www.neurocrine.com

### Neurocrine Biosciences Medical Affairs – Booth #207

12780 El Camino Real San Diego, CA 92130 www.neurocrine.com

#### Optum - Booth #300

1100 Optum Circle Eden Prairie, MN 55344 https://www.workatoptum.com

#### PsychU - Booth #114

508 Carnegie Center Princeton, NJ 08540 www.psychu.org

### 2022 Exhibitor Listing

### Quest Healthcare, a Division on Quest Products, LLC. – Booth #317

8201 104<sup>th</sup> Street Pleasant Prairie, WI 53158 www.questhealthcare.net

#### QuickChange/UI Medical - Booth #315

555 E. Ocean Blvd., Suite 400 Long Beach, CA 90802 www.quickchange.com

#### Right at Home - Booth #218

6700 Mercy Road Omaha, NE 68106 www.rightathome.net

#### The Rose Program - Booth #221

2000 Cliff Mine Road, Suite 500 Pittsburgh, PA 15275 Roseprogram.com

#### Salix Pharmaceuticals - Booth #212

400 Somerset Corporate Blvd Bridgewater, NJ 08807 www.salix.com

#### Sanofi - Booth #200

55 Corporate Drive Bridgewater, NJ 08807 www.sanofi.com

#### SK Life Science - Booth #220

461 From Rd Paramus, NJ 07652 www.sklifescienceinc.com

#### Smith&Nephew, Inc. - Booth #205

5600 Clearfork Main, Suite 600 Fort Worth, TX 76109

### Sorenson (formerly CaptionCall) – Booth #119

4215 S Riverboat Rd Salt Lake City, UT 84123 www.captioncall.com/professional

#### SUN Pharma - Booth #206

2 Independence Way Princeton, NJ 08540 www.sunpharma.com/usa

### Sunovion Pharmaceuticals, Inc. – Booth #204

84 Waterford Drive Marlborough, MA 01752

#### TeamHealth - Booth #320

265 Brookview Centre Way, Suite 400 Knoxville, TN 37919 www.teamhealth.com/join-teamhealth/

#### Teva Pharmaceuticals - Booth #122

400 Interpace Parkway Parsippany, NJ teva.com

#### Theo Medical Dermatology - Booth 117B

3030 East Semoran Blvd, Suite 258 Apopka, FL 32703 www.supporttheomedicaldermatology.com

### UCLA - Alzheimer's and Dementia Care Program – Booth #321

10945 Le Conte Ave. Suite 2339 Los Angeles, CA 90095 https://www.adcprogram.org

### The University of St. Augustine for Health Sciences – Booth #216

700 Windy Point Ln San Marcos, CA 92069 www.usa.edu

### University of Texas at Arlington – Booth #219

701 S. Nedderman Drive Arlington, TX 76019 www.academicpartnerships.uta.edu

#### Urovant Sciences - Booth #104

5281 California Ave., Suite 100 Irvine, CA 92617 www.urovant.com

#### Viatris Pharmaceuticals - Booth #124

1000 Myan Blvd Canonsburg, PA 15317 https://www.viatris.com/en

#### Xeris Pharmaceuticals - Booth #309

180 N. LaSalle Street, Suite 1600 Chicago, IL 60601 www.gvokeglucagon.com

While all reasonable care was taken in the exhibitor listing, there is always the possibility of error. We apologize if any inaccuracies are found. GAPNA assumes no liability for the accuracy of the information or omission of information.

### **Gerontological Advanced Practice Nurses Association** (GAPNA)

### **Annual Conference** 2023 Call for General, Concurrent, or **Pre-Conference Workshop Abstracts**

Visit gapna.org for complete submission specifications.

The GAPNA Planning Committee seeks abstract submissions for general session, concurrent session, or pre-conference workshop.

Presentation topics may address clinical best practices, innovative models of care, organizational change, unique strategies, and/or processes that improve outcomes and bridge gaps in care, analyses of current care, or case studies and be appropriate for presentation for APNs at an advanced level. Topic examples:

- APN roles & responsibilities
- Advanced clinical topics

- Acute care of older adults
- Preventive health care in the older adult
- Mental health of the older adult
  - Cost-effectiveness of APNs
- Advanced dimediatopics
   Chronic disease management
   Pain management
   Organizational issues and leadership
   Innovative clinical or practice projects

  - Patient education programs
    - New or adapted systems of care

### Submission Deadline

Abstracts must be received in the National Office by 12:00 am (midnight) Eastern time on December 5th.

#### **Guidelines for Submission**

Visit gapna.org for complete submission specifications. Abstracts should be submitted using the format provided on the GAPNA website.

### **Review and Acceptance**

Abstracts are reviewed and selected by members of the GAPNA Planning Committee. Selection is based on applicability to the care of older adults, significance of theory or practice, clarity, quality of content, and originality.

### Abstract Submission

**Kristina Moran, Education Coordinator GAPNA National Office** 

East Holly Avenue, Box 56 Pitman, NJ 08071-0056

Email (preferred): kristina.moran@ajj.com

Telephone: 856-256-2358

## Gerontological Advanced Practice Nurses Association (GAPNA)

### Annual Conference 2023 Call for Poster and Podium Abstracts

Visit gapna.org for complete submission specifications.

The GAPNA Education and Research Committees invite GAPNA members (current or upon abstract submission) to submit an abstract about their innovative work at the annual conference. Presentations should enrich the advanced practice registered nurse's knowledge and/or enhance the care of the older adult. Topics pertaining to advances in gerontological research or innovations in clinical practice change, nurse practitioner and clinical nurse specialist roles or educational programs, or patient education are encouraged.

First author of abstract selected for poster or oral podium presentation will be eligible for an award from the GAPNA Foundation. Select winning abstracts may be published in the GAPNA Newlsetter, on the GAPNA website, or in the journal, *Geriatric Nursing*.

#### **Submission Deadline**

Abstracts must be received in the National Office by 12:00 am (midnight) Eastern time on March 15th.

### **Guidelines for Submission**

Visit gapna.org for complete submission specifications. Abstracts should be submitted using the format provided on the GAPNA website.

### **Review and Acceptance**

Abstracts are reviewed and selected by members of the GAPNA Education and Research Committees. Selection is based on interest to advanced practice nursing, contribution to the care of older adults, clarity, and content. Innovative educational-focused abstracts should include enrichment of the knowledge of students, clients, and/or healthcare providers and identify NP or CNS national competencies or evidence-based guidelines, as appropriate.

#### Abstract Submission

Kristina Moran, Education Coordinator GAPNA National Office

East Holly Avenue, Box 56 Pitman, NJ 08071-0056

Email (preferred): kristina.moran@ajj.com

Telephone: 856-256-2358

### **Passport to Prizes**

See the flyer in your attendee bag for more information!



### **Attend to Win!**


When you attend any of our Industry Supported Product Theaters, you will be entered into a drawing by GAPNA to win one of our Michael Kors Bags.

The more ISPTs you attend, the more chances you have to win.

## Check out the Leader Board Challenge

and win prizes for your participation.





## In January 2022, GAPNA launched its official podcast GAPNA Chat.

Host, Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, provides interviews and discussions with GAPNA leaders and members of the gerontological health care community, and will focus on advocacy, policy, education, professional development, research, and clinical care for older adults.

### New episodes will be released bi-weekly.

Listen on the GAPNA Website or subscribe on Apple Podcasts, Google Podcasts, Spotify, Stitcher, TuneIn Radio, Spreaker, and other podcast delivery services.















## PHARMACOLOGY & Prescribing in Older Adults



### ORGANIZED AND FUNDED BY EISAI A L Z H E I M E R 'S D I S E A S E S Y M P O S I U M



HYATT REGENCY GRAND CYPRESS ROOM: GRAND CYPRESS G



PRESENTED BY

MALAZ A. BOUSTANI, MD
CENTER FOR AGING RESEARCH AT
IU SCHOOL OF MEDICINE
INDIANAPOLIS, IN



PRESENTED BY

SHARON COHEN, MD, FRCPC TORONTO MEMORY PROGRAM NORTH YORK, CANADA

### **AGENDA**

Introduction

**Challenges to Timely Diagnosis** 

**Treatment Outcomes: What Matters to Patients and Care Partners** 

Meeting space has been assigned to provide an Industry Supported Presentation Theater (ISPT) supported by Eisai during GAPNA's 2022 Annual Conference, September 14 - September 17 in Orlando. GAPNA's assignment of meeting space does not imply product endorsement nor does GAPNA assume any responsibility for the educational content of the ISPT.





### **PLEASE JOIN US**

# Recognition and Treatment of Tardive Dyskinesia With a Focus on Older Populations

#### **PROGRAM INFORMATION**

Thursday, September 15, 2022 12:30 pm-1:30 pm ET Grand Cypress A Lower Lobby Level Hyatt Regency Grand Cypress Orlando, FL

Lunch will be provided by Neurocrine

### Please visit us at Booth 304

As required by the U.S. Sunshine Act, Neurocrine will track and report to government agencies the cost of meals provided to individual health care professionals in connection with attendance at this promotional educational program. This information will be made publicly available. If you wish to not partake in the meal, please "opt out" of the meal when signing in. Neurocrine will not provide alcohol at this program.

HCPs licensed in Vermont and Minnesota are prohibited from partaking in a meal during this program. Please check the "opt-out" option when signing in.

The speaker is presenting on behalf of and is a paid consultant for Neurocrine Biosciences.

Meeting space has been assigned to provide an Industry Supported Presentation Theater (ISPT) supported by Neurocrine Biosciences, Inc. during GAPNA's 2022 Annual Conference, September 14–September 17 in Orlando. GAPNA's assignment of meeting space does not imply product endorsement nor does GAPNA assume any responsibility for the educational content of the ISPT.

#### PRESENTED BY



Elizabeth Elliott, PMHNP-BC
BH Director
Desert Peak Care Center
Phoenix, AZ

#### **PROGRAM OBJECTIVES**

- > Provide a brief overview of tardive dyskinesia (TD), including clinical features and impact on long-term care residents
- > Discuss a process for recognizing and diagnosing TD in long-term care residents receiving antipsychotics
- Review efficacy and safety data for an FDA-approved treatment option for older adults with TD, as well as treatment considerations

#### Important Information

### **INDICATION & USAGE**

INGREZZA® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

### **IMPORTANT SAFETY INFORMATION**

#### **CONTRAINDICATIONS**

INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.

### **WARNINGS & PRECAUTIONS**

### Somnolence

INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.

### **QT Prolongation**

INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

#### WARNINGS & PRECAUTIONS (continued)

#### **Parkinsonism**

INGREZZA may cause parkinsonism in patients with tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms.

### ADVERSE REACTIONS

The most common adverse reaction (≥5% and twice the rate of placebo) is somnolence. Other adverse reactions (≥2% and >Placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at **www.fda.gov/medwatch** or call 1-800-FDA-1088.

Please see adjacent page for INGREZZA Brief Summary of Prescribing Information or visit https://www.neurocrine.com/ingrezzapi for full Prescribing Information.





**Brief Summary:** for full Prescribing Information and Patient Information, refer to package insert.

#### INDICATION AND USAGE

INGREZZA® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

#### CONTRAINDICATIONS

INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.

#### **WARNINGS AND PRECAUTIONS**

#### Somnolence

INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA

#### QT Prolongation

INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA concentrations may be higher and QT prolongation clinically significant. For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. For patients taking a strong CYP3A4 inhibitor, reduce the dose of INGREZZA to 40 mg once daily. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

#### Parkinsonism 4 6 1

INGREZZA may cause parkinsonism in patients with tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. In the 3 placebo-controlled clinical studies in patients with tardive dyskinesia, the incidence of parkinson-like adverse events was 3% of patients treated with INGREZZA and <1% of placebo-treated patients. Postmarketing safety reports have described parkinson-like symptoms, some of which were severe and required hospitalization. In most cases, severe parkinsonism occurred within the first 2 weeks after starting or increasing the dose of INGREZZA. Associated symptoms have included falls, gait disturbances, tremor, drooling, and hypokinesia. In cases in which follow-up clinical information was available, parkinson-like symptoms were reported to resolve following discontinuation of INGREZZA therapy. Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms.

#### **ADVERSE REACTIONS**

The following adverse reactions are discussed in more detail in other sections of the labeling:

- Hypersensitivity
- Somnolence
- QT Prolongation
- Parkinsonism

#### **Clinical Trials Experience**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

### Variable and Fixed Dose Placebo-Controlled Trial Experience

The safety of INGREZZA was evaluated in 3 placebo-controlled studies, each 6 weeks in duration (fixed dose, dose escalation, dose reduction), including 445 patients. Patients were 26 to 84 years of age with moderate to severe tardive dyskinesia and had concurrent diagnoses of mood disorder (27%) or schizophrenia/ schizoaffective disorder (72%). The mean age was 56 years. Patients were 57% Caucasian, 39% African-American, and 4% other. With respect to ethnicity, 28% were Hispanic or Latino. All subjects continued previous stable regimens of antipsychotics; 85% and 27% of subjects, respectively, were taking atypical and typical antipsychotic medications at study entry.

Adverse Reactions Leading to Discontinuation of Treatment

A total of 3% of INGREZZA treated patients and 2% of placebo-treated patients discontinued because of adverse reactions.

Common Adverse Reactions

Adverse reactions that occurred in the 3 placebo-controlled studies at an incidence of  $\ge 2\%$  and greater than placebo are presented in Table 1.

Table 1: Adverse Reactions in 3 Placebo-Controlled Studies of 6-week Treatment Duration Reported at ≥2% and >Placebo

| Adverse Reaction <sup>1</sup>  | INGREZZA<br>(n=262) (%) | Placebo<br>(n=183) (%) |
|--|-------------------------|------------------------|
| General Disorders  |                         |                        |
| Somnolence (somnolence, fatigue, sedation)   | 10.9%                   | 4.2%                   |
| Nervous System Disorders   |                         |                        |
| Anticholinergic effects (dry mouth, constipation, disturbance in attention, vision blurred, urinary retention) | 5.4%                    | 4.9%                   |
| Balance disorders/fall (fall, gait disturbance, dizziness, balance disorder)                                   | 4.1%                    | 2.2%                   |
| Headache   | 3.4%                    | 2.7%                   |
| Akathisia (akathisia, restlessness)  | 2.7%                    | 0.5%                   |
| Gastrointestinal Disorders   |                         |                        |
| Vomiting   | 2.6%                    | 0.6%                   |
| Nausea   | 2.3%                    | 2.1%                   |
| Musculoskeletal Disorders  |                         |                        |
| Arthralgia   | 2.3%                    | 0.5%                   |

<sup>1</sup> Within each adverse reaction category, the observed adverse reactions are listed in order of decreasing frequency.

Other Adverse Reactions Observed During the Premarketing Evaluation of INGREZZA

Other adverse reactions of ≥1% incidence and greater than placebo are shown below. The following list does not include adverse reactions: 1) already listed in previous tables or elsewhere in the labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have clinically significant implications, or 5) which occurred at a rate equal to or less than placebo.

Endocrine Disorders: blood glucose increased

General Disorders: weight increased

Infectious Disorders: respiratory infections

Neurologic Disorders: drooling, dyskinesia, extrapyramidal symptoms (non-akathisia)

Psychiatric Disorders: anxiety, insomnia

During controlled trials, there was a dose-related increase in prolactin. Additionally, there was a dose-related increase in alkaline phosphatase and bilirubin, suggesting a potential risk for cholestasis.

#### Postmarketing Experience

The following adverse reactions have been identified during post-approval use of INGREZZA that are not included in other sections of labeling. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders: hypersensitivity reactions (including allergic dermatitis, angioedema, pruritis, and urticaria)

Skin and Subcutaneous Tissue Disorders: rash

### **DRUG INTERACTIONS**

Drugs Having Clinically Important Interactions with INGREZZA

Table 2: Clinically Significant Drug Interactions with INGREZZA

|                              | ant Drug Interactions with INGREZZA  |  |
|------------------------------|--|--|
| Monoamine Oxidase Inhibito   | · ,  |  |
| Clinical Implication:        | Concomitant use of INGREZZA with MAOIs may increase the concentration of monoamine neurotransmitters in synapses, potentially leading to increased risk of adverse reactions such as serotonin syndrome, or attenuated treatment effect of INGREZZA.   |  |
| Prevention or Management:    | Avoid concomitant use of INGREZZA with MAOIs.  |  |
| Examples:                    | isocarboxazid, phenelzine, selegiline  |  |
| Strong CYP3A4 Inhibitors     |  |  |
| Clinical Implication:        | Concomitant use of INGREZZA with strong CYP3A4 inhibitors increased the exposure (Cmax and AUC) to valbenazine and its active metabolite compared with the use of INGREZZA alone. Increased exposure of valbenazine and its active metabolite may increase the risk of exposure-related adverse reactions. |  |
| Prevention or Management:    | Reduce INGREZZA dose when INGREZZA is coadministered with a strong CYP3A4 inhibitor.   |  |
| Examples:                    | itraconazole, ketoconazole, clarithromycin   |  |
| Strong CYP2D6 Inhibitors     |  |  |
| Clinical Implication:        | Concomitant use of INGREZZA with strong CYP2D6 inhibitors increased the exposure ( $C_{\text{max}}$ and AUC) to valbenazine's active metabolite compared with the use of INGREZZA alone. Increased exposure of active metabolite may increase the risk of exposure-related adverse reactions.              |  |
| Prevention or Management:    | Reduce INGREZZA dose when INGREZZA is coadministered with a strong CYP2D6 inhibitor.   |  |
| Examples:                    | paroxetine, fluoxetine, quinidine  |  |
| Strong CYP3A4 Inducers       |  |  |
| Clinical Implication:        | Concomitant use of INGREZZA with a strong CYP3A4 inducer decreased the exposure of valbenazine and its active metabolite compared to the use of INGREZZA alone. Reduced exposure of valbenazine and its active metabolite may reduce efficacy.   |  |
| Prevention or Management:    | Concomitant use of strong CYP3A4 inducers with INGREZZA is not recommended.  |  |
| Examples:                    | rifampin, carbamazepine, phenytoin, St. John's wort <sup>1</sup>   |  |
| Digoxin                      |  |  |
| Clinical Implication:        | Concomitant use of INGREZZA with digoxin increased digoxin levels because of inhibition of intestinal P-glycoprotein (P-gp).   |  |
| Prevention or<br>Management: | Digoxin concentrations should be monitored when coadministering INGREZZA with digoxin. Increased digoxin exposure may increase the risk of exposure-related adverse reactions. Dosage adjustment of digoxin may be necessary.  |  |

<sup>&</sup>lt;sup>1</sup> The induction potency of St. John's wort may vary widely based on preparation.

#### Drugs Having No Clinically Important Interactions with INGREZZA

Dosage adjustment for INGREZZA is not necessary when used in combination with substrates of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2C19, CYP2E1, or CYP3A4/5 based on *in vitro* study results.

### OVERDOSAGE

### **Human Experience**

The pre-marketing clinical trials involving INGREZZA in approximately 850 subjects do not provide information regarding symptoms with overdose.

#### Management of Overdosage

No specific antidotes for INGREZZA are known. In managing overdose, provide supportive care, including close medical supervision and monitoring, and consider the possibility of multiple drug involvement. If an overdose occurs, consult a Certified Poison Control Center (1-800-222-1222 or www.poison.org).

For further information on INGREZZA, call 84-INGREZZA (844-647-3992).

